Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $52.56

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, Marketbeat reports. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $52.56.

Several equities research analysts recently weighed in on the stock. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. HC Wainwright cut their price objective on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. William Blair lowered Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company increased their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $10.20 on Thursday. The firm has a market capitalization of $413.20 million, a PE ratio of -1.96 and a beta of 1.39. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00. The firm’s 50-day moving average is $20.35 and its two-hundred day moving average is $42.86.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC increased its stake in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after purchasing an additional 2,964 shares during the last quarter. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics in the third quarter valued at $89,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics in the fourth quarter valued at $90,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.